Latest Ansell (ASX:ANN) News

Artificial intelligence stocks led the week, while miners and established companies delivered a broad run of stronger profits and dividends.
Large price gaps also showed that good company news did not always produce lasting buying.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

Ansell Limited (ASX:ANN) reported a robust FY26 with net profit doubling to US$208.6 million, driven by strong sales growth and operational resilience amid geopolitical challenges. The company also announced a leadership change and reaffirmed its sustainability ambitions.

Avecho and Chimeric both surged as traders chased near-term trial and funding catalysts, while Island Pharmaceuticals extended gains on a US biodefence partnership. Elsewhere, distribution and reimbursement wins supported smaller medtech names, and a cannabis merger plan kept Little Green Pharma in focus ahead of April’s vote.

Ansell Limited has updated its FY26 interim dividend details, confirming a USD 0.266 per share payout and setting the Dividend Reinvestment Plan price at USD 22.24 per share. The dividend will be paid in US dollars with an Australian dollar equivalent of AUD 0.3768 per share.

Ansell Limited reported a robust 61.5% surge in net profit for the first half of FY26, driven by operational efficiencies and strategic acquisitions, while announcing a planned CEO transition.

Ansell Limited announces the retirement of CEO Neil Salmon after five years in the role, appointing Nathalie Ahlström as his successor to lead the company’s next phase of growth and innovation.

Ansell Limited delivered a robust FY25 performance driven by organic growth, successful Kimberly-Clark PPE integration, and productivity gains, while advancing sustainability goals and managing trade headwinds.

Ansell Limited has revealed unauthorized access to certain company data through vulnerabilities in licensed third-party software, with no disruption to operations. While most accessed data was non-sensitive, some confidential and personal information was involved.

Ansell Limited has updated its FY25 final dividend announcement, confirming the dividend amount, exchange rate, and Dividend Reinvestment Plan pricing, providing clarity for shareholders ahead of payment.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited reports robust FY25 growth driven by strong Industrial and Healthcare segments, completes KBU acquisition integration ahead of schedule, and announces a $200 million share buyback for FY26.